These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. DMD genotype correlations from the Duchenne Registry: Endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype. Wang RT; Barthelemy F; Martin AS; Douine ED; Eskin A; Lucas A; Lavigne J; Peay H; Khanlou N; Sweeney L; Cantor RM; Miceli MC; Nelson SF Hum Mutat; 2018 Sep; 39(9):1193-1202. PubMed ID: 29907980 [TBL] [Abstract][Full Text] [Related]
10. Clinical and mutational characteristics of Duchenne muscular dystrophy patients based on a comprehensive database in South China. Wang DN; Wang ZQ; Yan L; He J; Lin MT; Chen WJ; Wang N Neuromuscul Disord; 2017 Aug; 27(8):715-722. PubMed ID: 28318817 [TBL] [Abstract][Full Text] [Related]
11. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838 [TBL] [Abstract][Full Text] [Related]
12. Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study. Goemans NM; Tulinius M; van den Hauwe M; Kroksmark AK; Buyse G; Wilson RJ; van Deutekom JC; de Kimpe SJ; Lourbakos A; Campion G PLoS One; 2016; 11(9):e0161955. PubMed ID: 27588424 [TBL] [Abstract][Full Text] [Related]
14. A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping. Walmsley GL; Arechavala-Gomeza V; Fernandez-Fuente M; Burke MM; Nagel N; Holder A; Stanley R; Chandler K; Marks SL; Muntoni F; Shelton GD; Piercy RJ PLoS One; 2010 Jan; 5(1):e8647. PubMed ID: 20072625 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls. Mendell JR; Khan N; Sha N; Eliopoulos H; McDonald CM; Goemans N; Mercuri E; Lowes LP; Alfano LN; J Neuromuscul Dis; 2021; 8(4):469-479. PubMed ID: 33523015 [TBL] [Abstract][Full Text] [Related]
16. Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy. Zhang S; Qin D; Wu L; Li M; Song L; Wei C; Lu C; Zhang X; Hong S; Ma M; Wu S; Orphanet J Rare Dis; 2021 Apr; 16(1):188. PubMed ID: 33910603 [TBL] [Abstract][Full Text] [Related]
17. Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy. Mercuri E; Signorovitch JE; Swallow E; Song J; Ward SJ; ; Neuromuscul Disord; 2016 Sep; 26(9):576-83. PubMed ID: 27423700 [TBL] [Abstract][Full Text] [Related]
18. Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients. Helderman-van den Enden AT; Straathof CS; Aartsma-Rus A; den Dunnen JT; Verbist BM; Bakker E; Verschuuren JJ; Ginjaar HB Neuromuscul Disord; 2010 Apr; 20(4):251-4. PubMed ID: 20153965 [TBL] [Abstract][Full Text] [Related]
19. The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy. Brogna C; Coratti G; Rossi R; Neri M; Messina S; Amico A; Bruno C; Lucibello S; Vita G; Berardinelli A; Magri F; Ricci F; Pedemonte M; Mongini T; Battini R; Bello L; Pegoraro E; Baranello G; Politano L; Comi GP; Sansone VA; Albamonte E; Donati A; Bertini E; Goemans N; Previtali S; Bovis F; Pane M; Ferlini A; Mercuri E; Neuromuscul Disord; 2021 Jun; 31(6):479-488. PubMed ID: 33773883 [TBL] [Abstract][Full Text] [Related]
20. Use of multiplex ligation-dependent probe amplification (MLPA) for Duchenne muscular dystrophy (DMD) gene mutation analysis. Murugan S; Chandramohan A; Lakshmi BR Indian J Med Res; 2010 Sep; 132():303-11. PubMed ID: 20847377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]